{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:14:25Z","timestamp":1779236065800,"version":"3.51.4"},"reference-count":29,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2010,6]]},"abstract":"ABSTRACT<\/jats:title>\n \n A population pharmacokinetic model of doripenem was constructed using data pooled from phase 1, 2, and 3 studies utilizing nonlinear mixed effects modeling. A 2-compartment model with zero-order input and first-order elimination best described the log-transformed concentration-versus-time profile of doripenem. The model was parameterized in terms of total clearance (CL), central volume of distribution (\n \n V\n c<\/jats:sub>\n <\/jats:italic>\n ), peripheral volume of distribution (\n \n V\n p<\/jats:sub>\n <\/jats:italic>\n ), and distribution clearance between the central and peripheral compartments (\n Q<\/jats:italic>\n ). The final model was described by the following equations (for\n j<\/jats:italic>\n th subject): CL\n \n j<\/jats:italic>\n <\/jats:sub>\n (liters\/h) = 13.6\u00b7(CL\n CR<\/jats:sub>\n \n j<\/jats:italic>\n <\/jats:sub>\n \/98 ml\/min)\n 0.659<\/jats:sup>\n \u00b7(1 + CL\n race<\/jats:sub>\n \n j<\/jats:italic>\n <\/jats:sub>\n [0 for Caucasian]);\n \n V\n c<\/jats:sub>\n <\/jats:italic>\n \n j<\/jats:italic>\n <\/jats:sub>\n (liters) = 11.6\u00b7(weight\n \n j<\/jats:italic>\n <\/jats:sub>\n \/73 kg)\n 0.596<\/jats:sup>\n ;\n \n Q\n j<\/jats:sub>\n <\/jats:italic>\n (liters\/h) = 4.74\u00b7(weight\n \n j<\/jats:italic>\n <\/jats:sub>\n \/73)\n 1.06<\/jats:sup>\n ; and\n \n V\n p<\/jats:sub>\n <\/jats:italic>\n \n j<\/jats:italic>\n <\/jats:sub>\n (liters) = 6.04\u00b7(CL\n CR<\/jats:sub>\n \n j<\/jats:italic>\n <\/jats:sub>\n \/98 ml\/min)\n 0.417<\/jats:sup>\n \u00b7(weight\n \n j<\/jats:italic>\n <\/jats:sub>\n \/73 kg)\n 0.840<\/jats:sup>\n \u00b7(age\n \n j<\/jats:italic>\n <\/jats:sub>\n \/40 years)\n 0.307<\/jats:sup>\n . According to the final model, population mean parameter estimates and interindividual variability (percent coefficient of variation [% CV]) for CL (liters\/h),\n \n V\n c<\/jats:sub>\n <\/jats:italic>\n (liters),\n \n V\n p<\/jats:sub>\n <\/jats:italic>\n (liters), and\n Q<\/jats:italic>\n (liters\/h) were 13.6 (19%), 11.6 (19%), 6.0 (25%), and 4.7 (42%), respectively. Residual variability, estimated using three separate additive residual error models, was 0.17 standard deviation (SD), 0.55 SD, and 0.92 SD for phase 1, 2, and 3 data, respectively. Creatinine clearance was the most significant predictor of doripenem clearance. Mean Bayesian clearance was approximately 33%, 55%, and 76% lower for individuals with mild, moderate, or severe renal impairment, respectively, than for those with normal renal function. The population pharmacokinetic model based on healthy volunteer data and patient data informs us of doripenem disposition in a more general population as well as of the important measurable intrinsic and extrinsic factors that significantly influence interindividual pharmacokinetic differences.\n <\/jats:p>","DOI":"10.1128\/aac.01649-09","type":"journal-article","created":{"date-parts":[[2010,4,13]],"date-time":"2010-04-13T03:45:08Z","timestamp":1271130308000},"page":"2354-2359","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":40,"title":["Population Pharmacokinetics of Doripenem Based on Data from Phase 1 Studies with Healthy Volunteers and Phase 2 and 3 Studies with Critically Ill Patients"],"prefix":"10.1128","volume":"54","author":[{"given":"Partha","family":"Nandy","sequence":"first","affiliation":[{"name":"Clinical Pharmacology, Advanced PK\/PD Modeling and Simulation, Johnson & Johnson Pharmaceutical Research & Development, LLC, Titusville, New Jersey 08560"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh N.","family":"Samtani","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Advanced PK\/PD Modeling and Simulation, Johnson & Johnson Pharmaceutical Research & Development, LLC, Titusville, New Jersey 08560"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Lin","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Advanced PK\/PD Modeling and Simulation, Johnson & Johnson Pharmaceutical Research & Development, LLC, Titusville, New Jersey 08560"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Antimicrob. Agents Chemother. 2004"},{"key":"e_1_3_2_3_2","unstructured":"NONMEM user guides parts I to VIII. 1988"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.9.3944-3947.2005"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00424-08"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009337012"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1472-8206.2003.00190.x"},{"key":"e_1_3_2_9_2","unstructured":"Guidance for industry: population pharmacokinetics. 1999"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2005.01271.x"},{"key":"e_1_3_2_11_2","first-page":"209","year":"1985","unstructured":"Gibaldi, M., and D. Perrier. 1985. Pharmacokinetics, 2nd ed., p. 209-211. Marcel Dekker, Inc., New York, NY.","journal-title":"Pharmacokinetics"},{"key":"e_1_3_2_12_2","unstructured":"Generalized additive models. 1993"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.18.12.1054"},{"key":"e_1_3_2_14_2","first-page":"379","volume":"7","year":"1977","unstructured":"Hinderling, P. H. 1977. Comparative studies of the protein binding of digoxin and its metabolites. Inflamm. Res.7:379-382.","journal-title":"Inflamm. Res."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2004.12.008"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868140-00007"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006291035"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02353864"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061469"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.Supplement_2.S249"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200039030-00002"},{"key":"e_1_3_2_22_2","unstructured":"Prescribing information. 2008"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/36.suppl_A.63"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00381-08"},{"key":"e_1_3_2_25_2","first-page":"142","year":"1989","unstructured":"Rowland, M., and T. M. Tozer. 1989. Clinical pharmacokinetics: concepts and applications, 2nd ed., p. 142-145. Lea and Febiger, Philadelphia, PA.","journal-title":"Clinical pharmacokinetics: concepts and applications"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061728"},{"key":"e_1_3_2_27_2","unstructured":"Antimicrob. Agents Chemother. 2004"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2009.01.027"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011555016423"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767070-00006"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01649-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01649-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:19:33Z","timestamp":1645474773000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01649-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1128\/AAC.01649-09"],"URL":"https:\/\/doi.org\/10.1128\/aac.01649-09","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"2009-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-03-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}